Type I interferon detection in autoimmune diseases: challenges and clinical applications

References

• Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202(1):8–32.
   PubMedGoogle Scholar
• Shows TB, Sakaguchi AY, Naylor SL, et al. Clustering of leukocyte and fibroblast interferon genes of human chromosome 9. Science. 1982;218(4570):373–374.
   PubMed Web of Science ®Google Scholar
• Eloranta M-L, Alm GV, Rönnblom L. Disease mechanisms in rheumatology--tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases. Arthritis Rheum. 2013;65(4):853–863.
   PubMedGoogle Scholar
• Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. 2006;25(3):373–381.
   PubMed Web of Science ®Google Scholar
• Prakash A, Smith E, Lee C, et al. Tissue-specific Positive Feedback Requirements for Production of Type I Interferon following Virus Infection. J Biol Chem. 2005;280(19):18651–18657.
   PubMed Web of Science ®Google Scholar
• Arpaia N, Barton GM. Toll-like Receptors: key Players in Antiviral Immunity. Curr Opin Virol. 2011;1(6):447–454.
   PubMed Web of Science ®Google Scholar
• Dixit E, Kagan JC. Intracellular pathogen detection by RIG-I-like receptors. Adv Immunol. 2013;117:99–125.
   PubMed Web of Science ®Google Scholar
• Sun L, Wu J, Du F, et al. Cyclic GMP-AMP Synthase is a Cytosolic DNA Sensor that Activates the Type-I Interferon Pathway. Internet]. 2013 [cited 2021 Jan 4];339. Available from Science. ; . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3863629/
   Web of Science ®Google Scholar
• Muskardin TLW, Niewold TB. Type I interferon in rheumatic diseases. Nat Rev Rheumatol. 2018;14(4):214–228.
   PubMed Web of Science ®Google Scholar
• Jensen MA, Niewold TB. Interferon regulatory factors: critical mediators of human lupus. Transl Res. 2015;165(2):283–295.
   PubMed Web of Science ®Google Scholar
• Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2011;1(6):519–525.
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5(5):375–386.
   PubMed Web of Science ®Google Scholar
• Hervas-Stubbs S, Perez-Gracia JL, Rouzaut A, et al. Direct effects of type I interferons on cells of the immune system. Clin Cancer Res. 2011;17(9):2619–2627.
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103.
   PubMed Web of Science ®Google Scholar
• Bengtsson AA, Rönnblom L. Role of interferons in SLE. Best Pract Res Clin Rheumatol. 2017;31(3):415–428.
   PubMed Web of Science ®Google Scholar
• Crow MK, Olferiev M, Kirou KA. Type I Interferons in Autoimmune Disease. Annu Rev Pathol. 2019;14(1):369–393.
   PubMedGoogle Scholar
• Rönnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016;34(4 Suppl 98):21–24.
   PubMed Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011;3(73):73ra19.
   PubMed Web of Science ®Google Scholar
• Lövgren T, Eloranta M-L, Båve U, et al. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004;50(6):1861–1872.
   PubMedGoogle Scholar
• Mazur DJ, Perrino FW. Identification and expression of the TREX1 and TREX2 cDNA sequences encoding mammalian 3ʹ-->5ʹ exonucleases. J Biol Chem. 1999;274(28):19655–19660.
   PubMed Web of Science ®Google Scholar
• Lood C, Gullstrand B, Truedsson L, et al. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis. Arthritis Rheum. 2009;60(10):3081–3090.
   PubMedGoogle Scholar
• Elkon KB, Santer DM. Complement, interferon and lupus. Curr Opin Immunol. 2012;24(6):665–670.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Elkon KB, Fitzgerald KA. Importance of Nucleic Acid Recognition in Inflammation and Autoimmunity. Annu Rev Med. 2016;67(1):323–336.
   PubMedGoogle Scholar
• Mahajan A, Herrmann M, Muñoz LE. Clearance Deficiency and Cell Death Pathways: a Model for the Pathogenesis of SLE. Front Immunol. 2016;7:35.
   PubMed Web of Science ®Google Scholar
• Crow MK. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease. Autoimmunity. 2010;43(1):7–16.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Sagalovskiy I, Guo Q, et al. Expression of Long Interspersed Nuclear Element 1 Retroelements and Induction of Type I Interferon in Patients With Systemic Autoimmune Disease. Arthritis Rheumatol. 2016;68(11):2686–2696.
   PubMed Web of Science ®Google Scholar
• Laska MJ, Troldborg A, Hansen B, et al. Polymorphisms within Toll-like receptors are associated with systemic lupus erythematosus in a cohort of Danish females. Rheumatology (Oxford). 2014;53(1):48–55.
   PubMed Web of Science ®Google Scholar
• Enevold C, Kjær L, Nielsen CH, et al. Genetic polymorphisms of dsRNA ligating pattern recognition receptors TLR3, MDA5, and RIG-I. Association with systemic lupus erythematosus and clinical phenotypes. Rheumatol Int. 2014;34(10):1401–1408.
   PubMed Web of Science ®Google Scholar
• Jermendy Á, Szatmári I, Körner A, et al. Association between interferon-induced helicase (IFIH1) rs1990760 polymorphism and seasonal variation in the onset of type 1 diabetes mellitus. Pediatr Diabetes. 2018;19(2):300–304.
   PubMed Web of Science ®Google Scholar
• Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet. 2006;38(6):617–619.
   PubMed Web of Science ®Google Scholar
• Robinson T, Kariuki SN, Franek BS, et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients. J Immunol. 2011;187(3):1298–1303.
   PubMed Web of Science ®Google Scholar
• Sutherland A, Davies J, Owen CJ, et al. Genomic Polymorphism at the Interferon-Induced Helicase (IFIH1) Locus Contributes to Graves’ Disease Susceptibility. J Clin Endocrinol Metab. 2007;92(8):3338–3341.
   PubMed Web of Science ®Google Scholar
• Varzari A, Bruch K, Deyneko IV, et al. Analysis of polymorphisms in RIG-I-like receptor genes in German multiple sclerosis patients. J Neuroimmunol. 2014;277(1–2):140–144.
   PubMed Web of Science ®Google Scholar
• Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity. 2010;32(3):305–315.
   PubMed Web of Science ®Google Scholar
• Zhang H, Pu J, Wang X, et al. IRAK1 rs3027898 C/A polymorphism is associated with risk of rheumatoid arthritis. Rheumatol Int. 2013;33(2):369–375.
   PubMed Web of Science ®Google Scholar
• Zhao W, Yue X, Liu K, et al. The status of pulmonary fibrosis in systemic sclerosis is associated with IRF5, STAT4, IRAK1, and CTGF polymorphisms. Rheumatol Int. 2017;37(8):1303–1310.
   PubMed Web of Science ®Google Scholar
• Doudar NA, Abdelshafy SS, Rady SAK, et al. Systemic lupus erythematosus: genetic variants in Xq28 region. Reumatologia. 2019;57(5):264–270.
   PubMedGoogle Scholar
• Liu X, Xing H, Gao W, et al. A functional variant in the OAS1 gene is associated with Sjögren’s syndrome complicated with HBV infection. Internet]. 2017 [cited 2021 Mar 14];7. Available from: Sci Rep. ; . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730593/
   PubMedGoogle Scholar
• Li H, Reksten TR, Ice JA, et al. Identification of a Sjögren’s syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. Internet]. 2017 [cited 2021 Mar 14];13. Available from: PLoS Genet. ; . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501660/
   Web of Science ®Google Scholar
• Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75(3):504–507.
   PubMed Web of Science ®Google Scholar
• Gourh P, Tan FK, Assassi S, et al. Association of the PTPN22 R620W polymorphism with anti-topoisomerase I- and anticentromere antibody-positive systemic sclerosis. Arthritis Rheum. 2006;54(12):3945–3953.
   PubMedGoogle Scholar
• Dieudé P, Guedj M, Wipff J, et al. The PTPN22620W allele confers susceptibility to systemic sclerosis: findings of a large case–control study of European Caucasians and a meta-analysis. Arthritis Rheum. 2008;58(7):2183–2188.
   PubMed Web of Science ®Google Scholar
• Orvain C, Assassi S, Avouac J, et al. Systemic sclerosis pathogenesis: contribution of recent advances in genetics. Curr Opin Rheumatol. 2020;32(6):505–514.
   PubMed Web of Science ®Google Scholar
• Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36(4):337–338.
   PubMed Web of Science ®Google Scholar
• Vlachogiannis NI, Nezos A, Tzioufas AG, et al. Increased frequency of the PTPN22W* variant in primary Sjogren’s Syndrome: association with low type I IFN scores. Clin Immunol. 2016;173:157–160.
   PubMed Web of Science ®Google Scholar
• Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3ʹ-5ʹ DNA exonuclease TREX1 cause Aicardi-Goutières syndrome at the AGS1 locus. Nat Genet. 2006;38(8):917–920.
   PubMed Web of Science ®Google Scholar
• Namjou B, Kothari PH, Kelly JA, et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011;12(4):270–279.
   PubMed Web of Science ®Google Scholar
• Hughes M, Little J, Herrick AL, et al. A synonymous variant in TREX1 is associated with systemic sclerosis and severe digital ischaemia. Scand J Rheumatol. 2017;46(1):77–78.
   PubMed Web of Science ®Google Scholar
• Fredi M, Bianchi M, Andreoli L, et al. Typing TREX1 gene in patients with systemic lupus erythematosus. Reumatismo. 2015;67(1):1–7.
   PubMed Web of Science ®Google Scholar
• Nezos A, Makri P, Gandolfo S, et al. TREX1 variants in Sjogren’s syndrome related lymphomagenesis. Cytokine. 2020;132:154781.
   PubMed Web of Science ®Google Scholar
• Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem. 2001;276(26):23382–23390.
   PubMed Web of Science ®Google Scholar
• Wang J-M, Huang A-F, Yuan Z-C, et al. Association of IRF5 rs2004640 polymorphism and systemic lupus erythematosus: a meta-analysis. Int J Rheum Dis. 2019;22(9):1598–1606.
   PubMed Web of Science ®Google Scholar
• Tang L, Chen B, Ma B, et al. Association between IRF5 polymorphisms and autoimmune diseases: a meta-analysis. Genet Mol Res. 2014;13(2):4473–4485.
   PubMed Web of Science ®Google Scholar
• Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A. 2007;104(16):6758–6763.
   PubMed Web of Science ®Google Scholar
• Stock CJW, De Lauretis A, Visca D, et al. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease. Clin Rheumatol. 2020;39(4):1173–1179.
   PubMed Web of Science ®Google Scholar
• Peng Y, Chen B, Sheng X, et al. Polymorphisms in IRF5 and TYK2 Genes Are Associated with Rheumatoid Arthritis in a Chinese Han Population. Med Sci Monit. 2021;27:e928455.
   PubMed Web of Science ®Google Scholar
• Dieudé P, Guedj M, Wipff J, et al. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 2009;60(1):225–233.
   PubMedGoogle Scholar
• Lessard CJ, Li H, Adrianto I, et al. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome. Nat Genet. Internet]. 2013 [cited 2019 Jul 3];45(11). doi:https://doi.org/10.1038/ng.2792
   Google Scholar
• Li Y, Chen S, Li P, et al. Association of the IRF5 rs2070197 polymorphism with systemic lupus erythematosus: a meta-analysis. Clin Rheumatol. 2015;34(9):1495–1501.
   PubMed Web of Science ®Google Scholar
• Fu Q, Zhao J, Qian X, et al. Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum. 2011;63(3):749–754.
   PubMedGoogle Scholar
• Carmona FD, Gutala R, Simeón CP, et al. Novel identification of the IRF7 region as an anticentromere autoantibody propensity locus in systemic sclerosis. Ann Rheum Dis. 2012;71(1):114–119.
   PubMed Web of Science ®Google Scholar
• Li S-W, He Y, Zheng Z-H, et al. Single-nucleotide polymorphisms of IRF8 gene are associated with systemic lupus erythematosus in Chinese Han population. Int J Immunogenet. 2014;41(2):112–118.
   PubMed Web of Science ®Google Scholar
• Leonard D, Svenungsson E, Sandling JK, et al. Coronary heart disease in systemic lupus erythematosus is associated with interferon regulatory factor-8 gene variants. Circ Cardiovasc Genet. 2013;6(3):255–263.
   PubMedGoogle Scholar
• Gorlova O, Martin J-E, Rueda B, et al. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 2011;53(7):e1002178.
   Google Scholar
• Arismendi M, Giraud M, Ruzehaji N, et al. Identification of NF-κB and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. Arthritis Res Ther. Internet]. 2015 [cited 2021 Feb 21];17. ;17:.
   PubMed Web of Science ®Google Scholar
• De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009;41(7):776–782.
   PubMed Web of Science ®Google Scholar
• Assassi S, Mayes MD, Arnett FC, et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum. 2010;62(2):589–598.
   PubMedGoogle Scholar
• Leyva L, Fernández O, Fedetz M, et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol. 2005;163(1–2):165–171.
   PubMed Web of Science ®Google Scholar
• Owens T, Khorooshi R, Wlodarczyk A, et al., Interferons in the central nervous system: a few instruments play many tunes. Glia. 62(3): 339–355. 2014.
   PubMed Web of Science ®Google Scholar
• Bieber AJ, Suwansrinon K, Kerkvliet J, et al. Allelic variation in the Tyk2 and EGF genes as potential genetic determinants of CNS repair. Proc Natl Acad Sci U S A. 2010;107(2):792–797.
   PubMed Web of Science ®Google Scholar
• Mero I-L, Lorentzen ÅR, Ban M, et al. A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis. Eur J Hum Genet. 2010;18(4):502–504.
   PubMed Web of Science ®Google Scholar
• Spach KM, Noubade R, McElvany B, et al. A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis. J Immunol. 2009;182:7776–7783.
   PubMed Web of Science ®Google Scholar
• Shapiro MR, Thirawatananond P, Peters L, et al. De-coding genetic risk variants in type 1 diabetes. Immunol Cell Biol. 2021;99(5):496–508.
   PubMed Web of Science ®Google Scholar
• Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491(7422):119–124.
   PubMed Web of Science ®Google Scholar
• Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus. N Engl J Med. 2007;357(10):977–986.
   PubMed Web of Science ®Google Scholar
• Wang J-M, Xu W-D, Huang A-F. Association of STAT4 Gene Rs7574865, Rs10168266 Polymorphisms and Systemic Lupus Erythematosus Susceptibility: a Meta-analysis. Immunol Invest. 2021;50(2–3):282–294.
   PubMed Web of Science ®Google Scholar
• Lee H-S, Remmers EF, Le JM, et al. Association of STAT4 with rheumatoid arthritis in the Korean population. Mol Med. 2007;13(9–10):455–460.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Ciccacci C, Priori R, et al. STAT4, TRAF3IP, IL10, and HCP5 Polymorphisms in Sjögren’s Syndrome: association with Disease Susceptibility and Clinical Aspects. J Immunol Res. Internet]. 2019 [cited 2019 Jul 2];22. Available from ;:1–8.
   Google Scholar
• Zheng J, Yin J, Huang R, et al. Meta-analysis reveals an association of STAT4 polymorphisms with systemic autoimmune disorders and anti-dsDNA antibody. Hum Immunol. 2013;74(8):986–992.
   PubMed Web of Science ®Google Scholar
• Korman BD, Alba MI, Le JM, et al. Variant form of STAT4 is associated with primary Sjögren’s syndrome. Genes Immun. 2008;9(3):267–270.
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kawaguchi Y, Goto K, et al. Positive association between STAT4 polymorphisms and polymyositis/dermatomyositis in a Japanese population. Ann Rheum Dis. 2012;71(10):1646–1650.
   PubMed Web of Science ®Google Scholar
• Dieudé P, Guedj M, Wipff J, et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 2009;60(8):2472–2479.
   PubMedGoogle Scholar
• Taylor KE, Remmers EF, Lee AT, et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet. 2008;4(5):e1000084.
   PubMed Web of Science ®Google Scholar
• Yi L, Wang JC, Guo XJ, et al. STAT4 is a Genetic Risk Factor for Systemic Sclerosis in a Chinese Population. Int J Immunopathol Pharmacol. 2013;26(2):473–478.
   PubMed Web of Science ®Google Scholar
• Svenungsson E, Gustafsson J, Leonard D, et al. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2010;69(5):834–840.
   PubMed Web of Science ®Google Scholar
• Hedrich CM, Tsokos GC. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med. 2011;17(12):714–724.
   PubMed Web of Science ®Google Scholar
• Cai T, Muhali F, Song R, et al. Genome-wide DNA methylation analysis in Graves’ disease. Genomics. 2015;105(4):204–210.
   PubMed Web of Science ®Google Scholar
• Chen S, Pu W, Guo S, et al. Genome-Wide DNA Methylation Profiles Reveal Common Epigenetic Patterns of Interferon-Related Genes in Multiple Autoimmune Diseases. Front Genet. Internet]. 2019 [cited 2021 Feb 28];10. Available from:. ; . : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459983/
   Web of Science ®Google Scholar
• Mavragani CP, Nezos A, Sagalovskiy I, et al. Defective regulation of L1 endogenous retroelements in primary Sjogren’s syndrome and systemic lupus erythematosus: role of methylating enzymes. J Autoimmun. 2018;88:75–82.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Kirou KA, Nezos A, et al. Expression of APOBEC family members as regulators of endogenous retroelements and malignant transformation in systemic autoimmunity. Clin Immunol. 2021;223:108649.
   PubMed Web of Science ®Google Scholar
• Goulielmos GN, Zervou MI, Vazgiourakis VM, et al. The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry. Gene. 2018;668:59–72.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Hua J, Lehman TJA, et al. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007;8(6):492–502.
   PubMed Web of Science ®Google Scholar
• Weckerle CE, Franek BS, Kelly JA, et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum. 2011;63(4):1044–1053.
   PubMed Web of Science ®Google Scholar
• Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52(5):1491–1503.
   PubMed Web of Science ®Google Scholar
• Chasset F, Ribi C, Trendelenburg M, et al. Identification of highly active systemic lupus erythematosus by combined type I interferon and neutrophil gene scores vs classical serologic markers. Rheumatology (Oxford). 2020;59(11):3468–3478.
   PubMed Web of Science ®Google Scholar
• Mai L, Asaduzzaman A, Noamani B, et al. The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther. 2021;23(1):29.
   PubMed Web of Science ®Google Scholar
• Flessa C-M, Vlachiotis S, Nezos A, et al. Independent association of low IFNλ1 gene expression and type I IFN score/IFNλ1 ratio with obstetric manifestations and triple antiphospholipid antibody positivity in primary antiphospholipid syndrome. Clin Immunol. 2019;209:108265.
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;6(1):e000270.
   PubMed Web of Science ®Google Scholar
• Zahn S, Rehkämper C, Kümmerer BM, et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus. J Invest Dermatol. 2011;131(1):133–140.
   PubMed Web of Science ®Google Scholar
• Sarkar MK, Hile GA, Tsoi LC, et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis. 2018;77(11):1653–1664.
   PubMed Web of Science ®Google Scholar
• Tucci M, Quatraro C, Lombardi L, et al. Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: role of interleukin-18. Arthritis Rheum. 2008;58(1):251–262.
   PubMedGoogle Scholar
• Peterson KS, Huang J-F, Zhu J, et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest. 2004;113(12):1722–1733.
   PubMed Web of Science ®Google Scholar
• Nzeusseu Toukap A, Galant C, Theate I, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum. 2007;56(5):1579–1588.
   PubMedGoogle Scholar
• Feinglass EJ, Arnett FC, Dorsch CA, et al. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976;55(4):323–339.
   PubMed Web of Science ®Google Scholar
• Van Dam AP. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int. 1991;11(1):1–11.
   PubMed Web of Science ®Google Scholar
• Hanly JG, Urowitz MB, Sanchez-Guerrero J, et al. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007;56(1):265–273.
   PubMed Web of Science ®Google Scholar
• Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol. 2011;9(3):449–457.
   PubMed Web of Science ®Google Scholar
• Reinert LS, Lopušná K, Winther H, et al. Sensing of HSV-1 by the cGAS-STING pathway in microglia orchestrates antiviral defence in the CNS. Nat Commun. 2016;7(1):13348.
   PubMed Web of Science ®Google Scholar
• Mondal TK, Saha SK, Miller VM, et al. Autoantibody-mediated neuroinflammation: pathogenesis of neuropsychiatric systemic lupus erythematosus in the NZM88 murine model. Brain Behav Immun. 2008;22(6):949–959.
   PubMed Web of Science ®Google Scholar
• Crupi R, Cambiaghi M, Spatz L, et al. Reduced adult neurogenesis and altered emotional behaviors in autoimmune-prone B-cell activating factor transgenic mice. Biol Psychiatry. 2010;67(6):558–566.
   PubMed Web of Science ®Google Scholar
• Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus. 2000;9(7):498–503.
   PubMed Web of Science ®Google Scholar
• Santer DM, Yoshio T, Minota S, et al., Potent Induction of IFN-α and Chemokines by Autoantibodies in the Cerebrospinal Fluid of Patients with Neuropsychiatric Lupus. J Immunol. 182(2): 1192–1201. 2009.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen K, Sloan SA, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34(36):11929–11947.
   PubMed Web of Science ®Google Scholar
• Goldmann T, Zeller N, Raasch J, et al., USP 18 lack in microglia causes destructive interferonopathy of the mouse brain. EMBO J. 34(12): 1612–1629. 2015.
   PubMed Web of Science ®Google Scholar
• Blank T, Prinz M. Type I interferon pathway in CNS homeostasis and neurological disorders. Glia. 2017;65(9):1397–1406.
   PubMed Web of Science ®Google Scholar
• Vaknin-Dembinsky A, Karussis D, Avichzer J, et al. NMO spectrum of disorders: a paradigm for astrocyte-targeting autoimmunity and its implications for MS and other CNS inflammatory diseases. J Autoimmun. 2014;54:93–99.
   PubMed Web of Science ®Google Scholar
• Van Heteren JT, Rozenberg F, Aronica E, et al. Astrocytes produce interferon-alpha and CXCL10, but not IL-6 or CXCL8, in Aicardi-Goutières syndrome. Glia. 2008;56(5):568–578.
   PubMed Web of Science ®Google Scholar
• Liu Y, Carlsson R, Ambjørn M, et al. PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients. J Neurosci. 2013;33(35):14231–14245.
   PubMed Web of Science ®Google Scholar
• Pashenkov M, Huang YM, Kostulas V, et al. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain. 2001;124(3):480–492.
   PubMedGoogle Scholar
• Kocur M, Schneider R, Pulm A-K, et al. IFNβ secreted by microglia mediates clearance of myelin debris in CNS autoimmunity. Acta Neuropathol Commun. 2015;3(1):20.
   PubMedGoogle Scholar
• Mavragani CP, Moutsopoulos HM. Sjögren syndrome. CMAJ. 2014;186(15):E579–E586.
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165(20):2337–2344.
   PubMedGoogle Scholar
• Skarlis C, Argyriou E, Mavragani CP. Lymphoma in Sjögren’s Syndrome: predictors and Therapeutic Options. CurrTreat Options Rheumatol. 2020;6(1):1–17.
   Web of Science ®Google Scholar
• Mavragani CP, Crow MK. Activation of the type I interferon pathway in primary Sjogren’s syndrome. J Autoimmun. 2010;35(3):225–231.
   PubMed Web of Science ®Google Scholar
• Wakamatsu E, Nakamura Y, Matsumoto I, et al. DNA microarray analysis of labial salivary glands of patients with Sjögren’s syndrome. Ann Rheum Dis. 2007;66(6):844–845.
   PubMed Web of Science ®Google Scholar
• Hjelmervik TOR, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren’s syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52(5):1534–1544.
   PubMed Web of Science ®Google Scholar
• Kimoto O, Sawada J, Shimoyama K, et al. Activation of the interferon pathway in peripheral blood of patients with Sjogren’s syndrome. J Rheumatol. 2011;38(2):310–316.
   PubMed Web of Science ®Google Scholar
• Nezos A, Gravani F, Tassidou A, et al. Type I and II interferon signatures in Sjogren’s syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren’s related lymphomagenesis. J Autoimmun. 2015;63:47–58.
   PubMed Web of Science ®Google Scholar
• Emamian ES, Leon JM, Lessard CJ, et al. Peripheral blood gene expression profiling in Sjögren’s syndrome. Genes Immun. 2009;10(4):285–296.
   PubMed Web of Science ®Google Scholar
• Brkic Z, Maria NI, Van Helden-meeuwsen CG, et al. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren’s syndrome and association with disease activity and BAFF gene expression. Ann Rheum Dis. 2013;72(5):728–735.
   PubMed Web of Science ®Google Scholar
• Imgenberg-Kreuz J, Sandling JK, Björk A, et al. Transcription profiling of peripheral B cells in antibody-positive primary Sjögren’s syndrome reveals upregulated expression of CX3CR1 and a type I and type II interferon signature. Scand J Immunol. 2018;87(5):e12662.
   PubMed Web of Science ®Google Scholar
• Bodewes ILA, Versnel MA. Interferon activation in primary Sjögren’s syndrome: recent insights and future perspective as novel treatment target. Expert Rev Clin Immunol. 2018;14(10):817–829.
   PubMed Web of Science ®Google Scholar
• Hillen MR, Pandit A, Blokland SLM, et al. Plasmacytoid DCs From Patients With Sjögren’s Syndrome Are Transcriptionally Primed for Enhanced Pro-inflammatory Cytokine Production. Front Immunol. 2019;10:2096.
   PubMed Web of Science ®Google Scholar
• Margaretten M. Neurologic Manifestations of Primary Sjögren Syndrome. Rheum Dis Clin North Am. 2017;43(4):519–529.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038.
   PubMed Web of Science ®Google Scholar
• Lande R, Giacomini E, Serafini B, et al. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J Immunol. 2004;173(4):2815–2824.
   PubMed Web of Science ®Google Scholar
• Cavanagh LL, Boyce A, Smith L, et al. Rheumatoid arthritis synovium contains plasmacytoid dendritic cells. Arthritis Res Ther. 2005;7(2):R230–240.
   PubMed Web of Science ®Google Scholar
• Van HJ, Tjm S, Blankert P, et al. Expression of interferon β in synovial tissue from patients with rheumatoid arthritis: comparison with patients with osteoarthritis and reactive arthritis. Ann Rheum Dis. 2005;64(12):1780–1782.
   PubMed Web of Science ®Google Scholar
• Van Der Pouw Kraan TCTM, Wijbrandts CA, Van Baarsen LGM, et al. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis. 2007;66(8):1008–1014.
   PubMed Web of Science ®Google Scholar
• Crow MK, Ronnblom L. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med. 2019;6(1):e000336.
   PubMed Web of Science ®Google Scholar
• Seyhan AA, Gregory B, Cribbs AP, et al. Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course. Sci Rep. 2020;10(1):8830.
   PubMed Web of Science ®Google Scholar
• Van Baarsen LGM, Bos WH, Rustenburg F, et al. Gene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritis. Arthritis Rheum. 2010;62(3):694–704.
   PubMedGoogle Scholar
• Van Der Pouw Kraan TCTM, Van Baarsen LGM, Wijbrandts CA, et al. Expression of a pathogen-response program in peripheral blood cells defines a subgroup of Rheumatoid Arthritis patients. Genes Immun. 2008;9(1):16–22.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, La DT, Stohl W, et al. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010;62(2):392–401.
   PubMedGoogle Scholar
• Roelofs MF, Wenink MH, Brentano F, et al. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Ann Rheum Dis. 2009;68(9):1486–1493.
   PubMed Web of Science ®Google Scholar
• Coclet-Ninin J, Dayer JM, Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw. 1997;8(4):345–349.
   PubMed Web of Science ®Google Scholar
• Palmer G, Mezin F, Juge-Aubry CE, et al. Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts. Ann Rheum Dis. 2004;63(1):43–49.
   PubMed Web of Science ®Google Scholar
• Triantaphyllopoulos KA, Williams RO, Tailor H, et al. Amelioration of collagen-induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis factor alpha production by interferon-beta gene therapy. Arthritis Rheum. 1999;42(1):90–99.
   PubMedGoogle Scholar
• Van Holten J, Reedquist K, Sattonet-Roche P, et al. Treatment with recombinant interferon-β reduces inflammation and slows cartilage destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther. 2004;6(3):R239–R249.
   PubMed Web of Science ®Google Scholar
• Wu M, Assassi S. The role of type 1 interferon in systemic sclerosis. Front Immunol. 2013;4:266.
   PubMed Web of Science ®Google Scholar
• Vlachogiannis NI, Pappa M, Ntouros PA, et al. Association Between DNA Damage Response, Fibrosis and Type I Interferon Signature in Systemic Sclerosis. Internet]. 2020 [cited 2021 Feb 27];11. Available from Front Immunol. ; . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566292/
   PubMed Web of Science ®Google Scholar
• Christmann RB, Sampaio-Barros P, Stifano G, et al. Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 2014;66(3):714–725.
   PubMed Web of Science ®Google Scholar
• Mireles-Canales MP, González-Chávez SA, Quiñonez-Flores CM, et al. DNA Damage and Deficiencies in the Mechanisms of Its Repair: implications in the Pathogenesis of Systemic Lupus Erythematosus. J Immunol Res. 2018;2018:8214379.
   PubMed Web of Science ®Google Scholar
• Martelli-Palomino G, Paoliello-Paschoalato AB, Crispim JCO, et al. DNA damage increase in peripheral neutrophils from patients with rheumatoid arthritis is associated with the disease activity and the presence of shared epitope. Clin Exp Rheumatol. 2017;35(2):247–254.
   PubMed Web of Science ®Google Scholar
• Skaug B, Assassi S. Type I interferon dysregulation in Systemic Sclerosis. Cytokine. 2020;132:154635.
   PubMed Web of Science ®Google Scholar
• Wuttge DM, Lood C, Tufvesson E, et al. Increased serum type I interferon activity in early systemic sclerosis patients is associated with antibodies against Sjögren’s syndrome antigens and nuclear ribonucleoprotein antigens. Scand J Rheumatol. 2013;42(3):235–240.
   PubMed Web of Science ®Google Scholar
• Lande R, Lee EY, Palazzo R, et al. CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. Nat Commun. 2019;10(1):1731.
   PubMedGoogle Scholar
• Lande R, Mennella A, Palazzo R, et al. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. Int J Mol Sci. 2020;21(14):21.
   Web of Science ®Google Scholar
• Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20(3):387–408.
   PubMed Web of Science ®Google Scholar
• Magro CM, Segal JP, Crowson AN, et al. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol. 2010;37(6):659–671.
   PubMed Web of Science ®Google Scholar
• McNiff JM, Kaplan DH. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008;35(5):452–456.
   PubMed Web of Science ®Google Scholar
• Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007;56(11):3784–3792.
   PubMed Web of Science ®Google Scholar
• Greenberg SA. A gene expression approach to study perturbed pathways in myositis. Curr Opin Rheumatol. 2007;19(6):536–541.
   PubMed Web of Science ®Google Scholar
• Niewold TB, Kariuki SN, Morgan GA, et al. Elevated Serum Interferon Alpha Activity in Juvenile Dermatomyositis: associations with Disease Activity at Diagnosis and After 36 Months of Therapy. Arthritis Rheum. 2009;60(6):1815–1824.
   PubMedGoogle Scholar
• Piper CJM, Wilkinson MGL, Deakin CT, et al. CD19+CD24hiCD38hi B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon-α. Front Immunol. 2018;9:1372.
   PubMed Web of Science ®Google Scholar
• Liao AP, Salajegheh M, Nazareno R, et al. Interferon β is associated with type 1 interferon-inducible gene expression in dermatomyositis. Ann Rheum Dis. 2011;70(5):831–836.
   PubMed Web of Science ®Google Scholar
• Somani A-K, Swick AR, Cooper KD, et al. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144(10):1341–1349.
   PubMedGoogle Scholar
• Cassius C, Amode R, Delord M, et al. MDA5+ Dermatomyositis Is Associated with Stronger Skin Type I Interferon Transcriptomic Signature with Upregulation of IFN-κ Transcript. J Invest Dermatol. 2020;140(6):1276–1279.e7.
   PubMed Web of Science ®Google Scholar
• De Souza HSP, Fiocchi C, Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat Rev Gastroenterol Hepatol. 2017;14(12):739–749.
   PubMed Web of Science ®Google Scholar
• Andreou N-P, Legaki E, Gazouli M. Inflammatory bowel disease pathobiology: the role of the interferon signature. Ann Gastroenterol. 2020;33(2):125–133.
   PubMed Web of Science ®Google Scholar
• Cantó E, Zamora C, Garcia-Planella E, et al. Bacteria-related Events and the Immunological Response of Onset and Relapse Adult Crohn’s Disease Patients. J Crohns Colitis. 2019;13(1):92–99.
   PubMed Web of Science ®Google Scholar
• Ito R, Shin-Ya M, Kishida T, et al., Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin Exp Immunol. 146(2): 330–338. 2006.
   PubMed Web of Science ®Google Scholar
• Kotredes KP, Thomas B, Gamero AM. The Protective Role of Type I Interferons in the Gastrointestinal Tract. Front Immunol. 2017;8:410.
   PubMed Web of Science ®Google Scholar
• Pott J, Stockinger S. Type I and III Interferon in the Gut: tight Balance between Host Protection and Immunopathology. Front Immunol. 2017;8:258.
   PubMed Web of Science ®Google Scholar
• McAleer JP, Kolls JK. Maintaining poise: commensal microbiota calibrate interferon responses. Immunity. 2012;37(1):10–12.
   PubMed Web of Science ®Google Scholar
• Santaolalla R, Abreu MT. Innate immunity in the small intestine. Curr Opin Gastroenterol. 2012;28(2):124–129.
   PubMed Web of Science ®Google Scholar
• Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet. 2003;361(9356):512–519.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Nezos A, Dovrolis N, et al. Type I and II Interferon Signatures Can Predict the Response to Anti-TNF Agents in Inflammatory Bowel Disease Patients: involvement of the Microbiota. Inflamm Bowel Dis. 2020;26(10):1543–1553.
   PubMed Web of Science ®Google Scholar
• Samie M, Lim J, Verschueren E, et al. Selective autophagy of the adaptor TRIF regulates innate inflammatory signaling. Nat Immunol. 2018;19(3):246–254.
   PubMed Web of Science ®Google Scholar
• Breese E, Braegger CP, Corrigan CJ, et al. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78(1):127–131.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329–342.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Niewold TB, Chatzigeorgiou A, et al. Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations. Front Immunol. 2013;4:238.
   PubMed Web of Science ®Google Scholar
• Fentiman IS, Thomas BS, Balkwill FR, et al. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet. 1985;325(8438):1166.
   Google Scholar
• Mandac JC, Chaudhry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 2006;43(4):661–672.
   PubMed Web of Science ®Google Scholar
• Lombardi A, Menconi F, Greenberg D, et al. Dissecting the Genetic Susceptibility to Graves’ Disease in a Cohort of Patients of Italian Origin. Front Endocrinol (Lausanne). 2016;7:21.
   PubMed Web of Science ®Google Scholar
• Corssmit EP, De Metz J, Sauerwein HP, et al. Biologic responses to IFN-alpha administration in humans. J Interferon Cytokine Res. 2000;20(12):1039–1047.
   PubMed Web of Science ®Google Scholar
• Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996;101(5):482–487.
   PubMed Web of Science ®Google Scholar
• Farrar JD, Murphy KM. Type I interferons and T helper development. Immunol Today. 2000;21(10):484–489.
   PubMedGoogle Scholar
• Caraccio N, Giannini R, Cuccato S, et al. Type I interferons modulate the expression of thyroid peroxidase, sodium/iodide symporter, and thyroglobulin genes in primary human thyrocyte cultures. J Clin Endocrinol Metab. 2005;90(2):1156–1162.
   PubMed Web of Science ®Google Scholar
• Monzani F, Caraccio N, Dardano A, et al. Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med. 2004;3(4):199–210.
   PubMed Web of Science ®Google Scholar
• Redondo MJ, Steck AK, Pugliese A. Genetics of type 1 diabetes. Pediatr Diabetes. 2018;19(3):346–353.
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69–82.
   PubMed Web of Science ®Google Scholar
• Lombardi A, Tsomos E, Hammerstad SS, et al. Interferon alpha: the key trigger of type 1 diabetes. J Autoimmun. 2018;94:7–15.
   PubMed Web of Science ®Google Scholar
• Fabris P, Betterle C, Floreani A, et al., Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet. 340(8818): 548. 1992.
   PubMed Web of Science ®Google Scholar
• Morgan NG, Leete P, Foulis AK, et al. Islet inflammation in human type 1 diabetes mellitus. IUBMB Life. 2014;66(11):723–734.
   PubMed Web of Science ®Google Scholar
• Huang X, Yuang J, Goddard A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes. 1995;44(6):658–664.
   PubMed Web of Science ®Google Scholar
• Chehadeh W, Weill J, Vantyghem MC, et al., Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: relationship with coxsackievirus B infection. J Infect Dis. 181(6): 1929–1939. 2000.
   PubMed Web of Science ®Google Scholar
• Xia C-Q, Peng R, Chernatynskaya AV, et al. Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production. J Immunol. 2014;193(3):1024–1034.
   PubMed Web of Science ®Google Scholar
• Winkler C, Lauber C, Adler K, et al. An interferon-induced helicase (IFIH1) gene polymorphism associates with different rates of progression from autoimmunity to type 1 diabetes. Diabetes. 2011;60(2):685–690.
   PubMed Web of Science ®Google Scholar
• Ferreira RC, Guo H, Coulson RMR, et al. A type I interferon transcriptional signature precedes autoimmunity in children genetically at risk for type 1 diabetes. Diabetes. 2014;63(7):2538–2550.
   PubMed Web of Science ®Google Scholar
• Diana J, Simoni Y, Furio L, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med. 2013;19(1):65–73.
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Satoh J, Takahashi K, et al. Complete suppression of insulitis and diabetes in NOD mice lacking interferon regulatory factor-1. J Autoimmun. 2001;17(2):119–125.
   PubMed Web of Science ®Google Scholar
• Stewart TA, Hultgren B, Huang X, et al. Induction of type I diabetes by interferon-alpha in transgenic mice. Science. 1993;260(5116):1942–1946.
   PubMed Web of Science ®Google Scholar
• Hirschfield GM, Beuers U, Corpechot C, European Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–172.
   PubMed Web of Science ®Google Scholar
• Takii Y, Nakamura M, Ito M, et al. Enhanced expression of type I interferon and toll-like receptor-3 in primary biliary cirrhosis. Lab Invest. 2005;85(7):908–920.
   PubMed Web of Science ®Google Scholar
• Bae HR, Hodge DL, Yang G-X, et al., The interplay of type I and type II interferons in murine autoimmune cholangitis as a basis for sex-biased autoimmunity. Hepatology. 67(4): 1408–1419. 2018.
   PubMed Web of Science ®Google Scholar
• Okada C, Akbar SMF, Horiike N, et al. Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I:C administration. Liver Int. 2005;25(3):595–603.
   PubMed Web of Science ®Google Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–2112.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805–815.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev. 2016;15(4):307–324.
   PubMed Web of Science ®Google Scholar
• Waters P, Woodhall M, O’Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e89.
   PubMed Web of Science ®Google Scholar
• Weber MS, Derfuss T, Brück W. Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Central Nervous System Demyelination-A Novel Disease Entity? JAMA Neurol. 2018;75(8):909–910.
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, De Seze J, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008;65(1):78–83.
   PubMedGoogle Scholar
• Krumbholz M, Faber H, Steinmeyer F, et al., Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 131(6): 1455–1463. 2008.
   PubMedGoogle Scholar
• Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry. 2018;89(9):927–936.
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010;16(12):1443–1452.
   PubMed Web of Science ®Google Scholar
• Khorooshi R, Wlodarczyk A, Asgari N, et al. Neuromyelitis optica-like pathology is dependent on type I interferon response. Exp Neurol. 2013;247:744–747.
   PubMed Web of Science ®Google Scholar
• Berg CT, Khorooshi R, Asgari N, et al., Influence of type I IFN signaling on anti-MOG antibody-mediated demyelination. J Neuroinflammation. 14(1): 127. 2017.
   PubMedGoogle Scholar
• Feng X, Reder NP, Yanamandala M, et al., Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J Neurol Sci. 313(1–2): 48–53. 2012.
   PubMed Web of Science ®Google Scholar
• Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169–180.
   PubMed Web of Science ®Google Scholar
• Reder AT, Feng X. How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms. J Interferon Cytokine Res. 2014;34(8):589–599.
   PubMed Web of Science ®Google Scholar
• Di Filippo M, Tozzi A, Tantucci M, et al. Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: electrophysiological evidence. Neurobiol Dis. 2014;62:387–393.
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788–1795.
   PubMed Web of Science ®Google Scholar
• Hannon CW, McCourt C, Lima HC, et al. Interventions for cutaneous disease in systemic lupus erythematosus. Cochrane Database Syst Rev. 2021;3:CD007478.
   PubMedGoogle Scholar
• Posada J, Valadkhan S, Burge D, et al. Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren’s Syndrome: a Randomized Clinical Trial. Arthritis Rheumatol. 2021;73(1):143–150.
   PubMed Web of Science ®Google Scholar
• McBride JM, Jiang J, Abbas AR, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 2012;64(11):3666–3676.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016;75(1):196–202.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75(11):1909–1916.
   PubMed Web of Science ®Google Scholar
• Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73(1):256–262.
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Thanou A, Mazur M, et al., IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study. Ann Rheum Dis. 79(3): 347–355. 2020.
   PubMed Web of Science ®Google Scholar
• Furie RA, Morand EF, Bruce IN, et al., Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1(4): e208–e219. 2019.
   PubMedGoogle Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N Engl J Med. 2020;382(3):211–221.
   PubMed Web of Science ®Google Scholar
• Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther. 2014;16(1):R57.
   PubMed Web of Science ®Google Scholar
• Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm. 2012;69:2120.
   Web of Science ®Google Scholar
• Mogul A, Corsi K, McAuliffe L. Baricitinib: the Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. Ann Pharmacother. 2019;53(9):947–953.
   PubMed Web of Science ®Google Scholar
• Kahl L, Patel J, Layton M, et al. Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus. Lupus. 2016;25(13):1420–1430.
   PubMed Web of Science ®Google Scholar
• Duggan S, Keam SJ. Upadacitinib: first Approval. Drugs. 2019;79(16):1819–1828.
   PubMed Web of Science ®Google Scholar
• Skarlis C, Marketos N, Mavragani CP. Biologics in Sjögren’s syndrome. Pharmacol Res. 2019;147:104389.
   PubMed Web of Science ®Google Scholar
• Jiang J, Zhao M, Chang C, et al. Type I Interferons in the Pathogenesis and Treatment of Autoimmune Diseases. Clin Rev Allergy Immunol. 2020;59(2):248–272.
   PubMed Web of Science ®Google Scholar
• Lacy M, Hauser M, Pliskin N, et al. The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Mult Scler. 2013;19(13):1765–1772.
   PubMed Web of Science ®Google Scholar
• Feng X, Han D, Kilaru BK, et al. Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins. Arch Neurol. 2012;69(10):1303–1309.
   PubMedGoogle Scholar
• Larsson PG, Lakshmikanth T, Laitinen OH, et al. A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia. 2015;58(2):346–354.
   PubMed Web of Science ®Google Scholar
• Moëll A, Skog O, Åhlin E, et al. Antiviral effect of nicotinamide on enterovirus-infected human islets in vitro: effect on virus replication and chemokine secretion. J Med Virol. 2009;81(6):1082–1087.
   PubMed Web of Science ®Google Scholar
• Wampler Muskardin TL, Fan W, Jin Z, et al. Distinct Single Cell Gene Expression in Peripheral Blood Monocytes Correlates With Tumor Necrosis Factor Inhibitor Treatment Response Groups Defined by Type I Interferon in Rheumatoid Arthritis. Front Immunol. 2020;11:1384.
   PubMed Web of Science ®Google Scholar
• Wampler Muskardin T, Vashisht P, Dorschner JM, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1757–1762.
   PubMed Web of Science ®Google Scholar
• Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. Arthritis Rheum. 2010;62(12):3607–3614.
   PubMedGoogle Scholar
• Quartuccio L, Mavragani CP, Nezos A, et al. Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren’s syndrome. Clin Exp Rheumatol. 2017;35(4):719–720.
   PubMed Web of Science ®Google Scholar
• Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. Brain. 2009;132(12):3353–3365.
   PubMedGoogle Scholar
• Axtell RC, De Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010;16(4):406–412.
   PubMed Web of Science ®Google Scholar
• Martin PK, Cadwell K. Regulation of interferon signaling in response to gut microbes by autophagy. Gut Microbes. 2020;11(1):126–134.
   PubMed Web of Science ®Google Scholar
• Van Baarsen LG, Wijbrandts CA, Rustenburg F, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. Arthritis Res Ther. 2010;12(1):R11.
   PubMed Web of Science ®Google Scholar